The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity

Oncotarget

Volumn 5, Issue 24, 2014, Pages 12728-12737

  Wagner, Jessica ^a,b   Kline, Christina Leah ^a,b   Pottorf, Richard S ^c   Nallaganchu, Bhaskara Rao ^c   Olson, Gary L ^c   Dicker, David T ^a,b   Allen, Joshua E ^d   El Deiry, Wafik S ^a,b  

^a PENN STATE CANCER INSTITUTE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c Provid Pharmaceuticals   (United States)

^d Oncoceutics   (United States)

Author keywords

Akt; Cancer; ERK; Foxo3a; ONC201; TIC10; TRAIL pathway

Indexed keywords

ANTINEOPLASTIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE; ONC 201; PROTEIN KINASE B; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; FUSED HETEROCYCLIC RINGS; TIC10 COMPOUND;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CELL VIABILITY; CONTROLLED STUDY; DRUG STRUCTURE; GENE EXPRESSION; HUMAN; HUMAN CELL; INFRARED SPECTROMETRY; MASS SPECTROMETRY; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TRAIL GENE; X RAY CRYSTALLOGRAPHY; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; INFRARED SPECTROPHOTOMETRY; NUCLEAR MAGNETIC RESONANCE IMAGING; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; MAGNETIC RESONANCE IMAGING; MASS SPECTROMETRY; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; SPECTROPHOTOMETRY, INFRARED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84921342086     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2890     Document Type: Article

References (8)

1. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM. The receptor for the cytotoxic ligand TRAIL. Science. 1997; 276:111-113.
2. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002; 2:420-430.
3. Kuribayashi K, Krigsfeld G, Wang W, Xu J, Mayes PA, Dicker DT, Wu GS, El-Deiry WS. TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biol Ther. 2008; 7:2034-2038.
4. Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, Dolloff NG, Messaris E, Scata KA, Wang W, Zhou JY, Wu GS, El-Deiry WS. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med. 2013; 5:171ra117.
5. Stähle H, Dr., Köppe H, Dr., Kummer W, Dr. Ingelheim. (1973). Imidazo-[1,2-a]-pyrido-[4,3-d]-pyrimidines, their acid addition salts and method for their manufacture. In: GERMANY FRO and OFFICE GP, eds. (Germany: C.H BOEHRINGER SOHN, INGELHEIM AM RHEIN).
6. Ghaffari S, Jagani Z, Kitidis C, Lodish HF, Khosravi-Far R. Cytokines and BCR-ABL mediate suppression of TRAILinduced apoptosis through inhibition of forkhead FOXO3a transcription factor. Proc Natl Acad Sci U S A. 2003; 100:6523-6528.
7. Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene. 2005; 24:7410-7425.
8. Jacob NT, Lockner JW, Kravchenko VV, Janda KD. Pharmacophore reassignment for induction of the immunosurveillance cytokine TRAIL. Angew Chem Int Ed Engl. 2014; 53:6628-6631.